Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23132525 | 0.93 | CYP4F2 (0.42) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL15070913 | 0.92 | CYP4F2 (0.54) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL10023943 | 0.88 | CYP4F2 (0.50) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL16150101 | 0.88 | CYP4F2 (0.50) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL27681347 | 0.85 | CYP4F2 (0.54) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL13762005 | 0.84 | CYP4F2 (0.36) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL1361264 | 0.84 | CYP4F2 (0.44) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL17248131 | 0.83 | CYP4F2 (0.44) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL13755066 | 0.79 | MEN1 (0.43) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL10118792 | 0.79 | CYP4F2 (0.42) | CYP4F2CYP4A11MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988339-B2 | Nonpolar phase-soluble metathesis catalysts | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180065914-A1 | RUTHENIUM POLYMERISATION CATALYSTS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2018-03-08 | — | — | US | disclosed |
| US-9815765-B2 | Ruthenium polymerisation catalysts | UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2017-11-14 | — | — | US | disclosed |
| US-20160264510-A1 | NONPOLAR PHASE-SOLUBLE METATHESIS CATALYSTS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2016-09-15 | — | — | US | disclosed |
| US-9370770-B2 | Nonpolar phase-soluble metathesis catalysts | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2016-06-21 | — | — | US | disclosed |
| US-9233994-B2 | Ruthenium complexes for use in olefin metathesis | UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2016-01-12 | — | — | US | disclosed |
| US-20150057449-A1 | NONPOLAR PHASE-SOLUBLE METATHESIS CATALYSTS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2015-02-26 | — | — | US | disclosed |
| US-20140228563-A1 | RUTHENIUM POLYMERISATION CATALYSTS | UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2014-08-14 | — | — | US | disclosed |
| US-20130165649-A1 | RUTHENIUM COMPLEXES FOR USE IN OLEFIN METATHESIS | UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065914-A1 | RUTHENIUM POLYMERISATION CATALYSTS | RRP12, PCBP1, PARG | CYP4F2 1707/4885CYP4A11 3716/4885MEN1 796/4885 |
| US-20150057449-A1 | NONPOLAR PHASE-SOLUBLE METATHESIS CATALYSTS | SIGMAR1, SUB1, PCBP1 | CYP4F2 967/4885CYP4A11 1574/4885MEN1 3609/4885 |
| US-20130165649-A1 | RUTHENIUM COMPLEXES FOR USE IN OLEFIN METATHESIS | OSBP, CYCS, OSBPL3 | CYP4F2 341/4885CYP4A11 2489/4885MEN1 2178/4885 |
| US-20140228563-A1 | RUTHENIUM POLYMERISATION CATALYSTS | RRP12, PCBP1, PARG | CYP4F2 1707/4885CYP4A11 3716/4885MEN1 796/4885 |
| US-20160264510-A1 | NONPOLAR PHASE-SOLUBLE METATHESIS CATALYSTS | RPA1, SUB1, PCBP1 | CYP4F2 1604/4885CYP4A11 2092/4885MEN1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.